Navigation Links
Celator(R) Pharmaceuticals Presents New Data on CPX-351 And CPX-1 at the American Association for Cancer Research
Date:4/22/2009

PRINCETON, N.J., April 22 /PRNewswire/ -- Celator Pharmaceuticals today announced that new data from animal studies of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection in consolidation treatment for leukemia and of CPX-1 (Irinotecan HCl:Floxuridine) Liposome Injection in combination with biological agents for the treatment of colorectal cancer were presented at the 100th Annual Meeting of the American Association for Cancer Research (AACR) in Denver, Colorado (Abstracts 4568 and 4578).

"Even as we progress through Phase 2 human clinical trials with both CPX-351 and CPX-1, our ongoing work in xenograft models of human cancer provides important additional direction regarding their potential place in current treatment paradigms," said Scott Jackson, chief executive officer, Celator Pharmaceuticals. "These studies, which further highlight the utility of maintaining synergistic molar ratios of chemotherapeutic agents through nano-scale delivery vehicles, also suggest strategies for enhancing clinical outcomes with CPX-351 in leukemia and CPX-1 in colorectal cancer."

In the first presentation, researchers reported that CPX-351 was superior to standard cytarabine:daunorubicin free-drug cocktail in ablating leukemic bone marrow cells in the CCRF-CEM human leukemia xenograft model. Additional data showed median survival was improved by consolidation treatment with either CPX-351 or free drug cocktail therapies but long-term survival (beyond 100 days) was achieved only with CPX-351 induction and consolidation therapy. Furthermore, it appeared that intermediate dosing frequencies (days 1 & 3 or days 1 & 5) for consolidation treatment with CPX-351 produced superior efficacy to a longer dosing frequency (days 1 & 7), with regard to both survival improvement and bone marrow drug accumulation. Recovery times of normal bone marrow cellularity following consolidation treatments were comparable among all three consolidation dosing schedules studied.

The second presentation examined the effects of combining CPX-1 with either bevacizumab (Avastin(R)) or cetuximab (Erbitux(R)), biological agents frequently used in combination with chemotherapy for treating metastatic colorectal cancer, in mice engrafted with human colon tumor cells. CPX-1 combined with bevacizumab significantly enhanced the efficacy observed in the LS174T colorectal xenograft model when compared to either drug used as a single agent. Furthermore, CPX-1 combined with cetuximab significantly enhanced the efficacy observed in the DLD-1 colorectal xenograft model when compared to either drug used as a single agent. In both experiments, the addition of the monoclonal antibody to CPX-1 enhanced or potentiated anti-tumor activity, suggesting that these combinations might augment the promising efficacy observed in prior studies of CPX-1 as monotherapy.

About Celator Pharmaceuticals, Inc.

Celator Pharmaceuticals, Inc., with locations in Princeton, NJ, and Vancouver, BC, is a privately held pharmaceutical company developing new and more effective therapies to treat cancer. CombiPlex(R), the company's proprietary drug ratio technology platform, represents a novel approach that identifies molar ratios of drugs that will deliver a synergistic benefit, and locks the desired ratio in a nano-scale drug delivery vehicle that maintains the ratio in patients with the goal of improving clinical outcomes. The company pipeline includes: CPX-351 (a liposomal formulation of cytarabine:daunorubicin), currently in Phase 2 in patients with acute myeloid leukemia; CPX-1 (a liposomal formulation of irinotecan:floxuridine), currently in Phase 2 in patients with colorectal cancer; CPX-571 (a liposomal formulation of irinotecan:cisplatin), a preclinical stage compound; and multiple research programs. Based on the applications of CombiPlex, Celator is positioned to advance a broad pipeline of combination therapies involving both previously approved and novel drug agents. For more information, please visit the company's website at www.celatorpharma.com. Information on ongoing trials is available at www.clinicaltrials.gov.

List of abstracts:

AACR Abstract #4568: Tardi P, Harasym T, Dos Santos N, et. al. CPX-351, a liposome formulation containing a synergistic 5:1 molar ratio of cytarabine (Cyt) and daunorubicin (Daun), exhibitis improved efficacy against human leukemia xenografts when administered at intermediate frequency in consolidation treatment. Poster presented Tuesday, April 21, 2009 (Hall B-F, Poster Section 33, Poster Board 1).

AACR Abstract #4578: Tardi P, Harasym T, Bermudes D, et al. CPX-1, a liposome formulation containing a synergistic 1:1 molar ratio of irinotecan and floxuridine, exhibits increased efficacy in combination with either bevacizumab (BEV) or cetuximab (CET) in human colorectal cancer (CRC) solid tumor xenograft models. Poster presented Tuesday, April 21, 2009 (Hall B-F, Poster Section 33, Poster Board 11).

Avastin(R) is a registered trademark of Genentech Inc.

Erbitux(R) is a registered trademark of ImClone Systems Incorporated


'/>"/>
SOURCE Celator Pharmaceuticals
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Frederick R. Appelbaum, M.D. and Ross C. Donehower, M.D. Join Scientific Advisory Board of Celator(R) Pharmaceuticals
2. Celator(R) Pharmaceuticals Presents Phase 1 Results With CPX-351 in Patients With Advanced Leukemia at the American Society of Hematology Meeting
3. Celator(R) Pharmaceuticals To Present at Biotech Showcase 2009
4. Celator(R) Pharmaceuticals Enrolls First Patient in Its Phase 2 Study of CPX-351 in Acute Myeloid Leukemia in First Relapse
5. Celator(R) Pharmaceuticals to Present at Future Leaders in the Biotech Industry Conference
6. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
7. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
8. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
9. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
10. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
11. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the benefits of moderation, whether ... latter, setting the bar too high can result in disappointment, perhaps even self-loathing. However, ... their goal. , Research from PsychTests.com reveals that behind the tendency ...
(Date:6/24/2016)... ... ... June 19, 2016 is World Sickle Cell Observance Day. In an effort to ... treatments, Serenity Recovery Center of Marne, Michigan, has issued a pain management ... (SCD) is a disorder of the red blood cells, which can cause episodes of ...
(Date:6/24/2016)... ... ... Global law firm Greenberg Traurig, P.A. announced that 20 Florida attorneys are recognized ... this recognition are considered among the top 2 percent of lawyers practicing within the ... this year’s Legal Elite Hall of Fame: Miami Shareholders Mark D. Bloom, Burt ...
(Date:6/24/2016)... ... June 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief ... a minimum wage raise to $12 an hour by 2020 and then adjusting it yearly ... lost value of the minimum wage, assure the wage floor does not erode again, and ...
(Date:6/24/2016)... York, NY (PRWEB) , ... June 24, 2016 ... ... publication Haute Living, is proud to recognize Dr. Barry M. Weintraub as a ... that “the most beautiful women in the world, and the most handsome men, ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... 23, 2016 Research and Markets ... Market by Type (Organic Chemical (Sugar, Petrochemical, Glycerin), Inorganic ... Coating, Parenteral) - Global Forecast to 2021" report ... The global pharmaceutical excipients market is projected to ... of 6.1% in the forecast period 2016 to 2021. ...
(Date:6/23/2016)... , June 23, 2016 ... CAPR ), a biotechnology company focused on the ... announced that patient enrollment in its ongoing randomized ... has exceeded 50% of its 24-patient target. Capricor ... the third quarter of 2016, and to report ...
(Date:6/23/2016)... and INDIANAPOLIS , June 23, ... a Lilly Diabetes Tomorrow,s Leaders Scholarship is any indication, ... winners, announced today online at www.diabetesscholars.org by ... 1 diabetes stand in the way of academic and ... the Foundation,s scholarship program since 2012, and continues to ...
Breaking Medicine Technology: